Last updated: August 11, 2025
Introduction
Patent CN111278414, titled “Method for Manufacturing a Pharmaceutical Composition,” represents a significant patent filing in China’s pharmaceutical sector. Its scope and claims are pivotal for understanding its protective boundaries, potential infringement risks, and positioning within the global patent landscape. This analysis delves into the specifics of the patent’s claims, their implications, and the broader patent environment in which CN111278414 operates.
Patent Overview
CN111278414 was filed on September 24, 2020, and granted on October 19, 2022, by the China National Intellectual Property Administration (CNIPA). The patent primarily aims to protect a novel method for producing a pharmaceutical composition, likely emphasizing process innovations that enhance efficiency, purity, or stability.
The patent claims focus on specific steps, reagents, and conditions that distinguish this manufacturing process from prior art. Its claims could potentially cover formulations with improved bioavailability, stability, or manufacturing efficiency, depending on the detailed description.
Scope of the Patent
Claim Structure and Focus
Typically, pharmaceutical process patents like CN111278414 comprise:
- Independent Claims: Broadly define the core process or composition, establishing the primary scope of patent protection.
- Dependent Claims: Narrower claims that specify particular embodiments, reaction conditions, reagents, or additives.
In CN111278414, the independent claims likely encompass a process involving a sequence of steps—such as specific mixing, heating, or purification procedures—that lead to a pharmaceutical product with desirable characteristics.
Key elements that define the scope include:
- Reaction Conditions: Temperatures, pH, solvents, and durations.
- Reagents: Specific chemical or biological agents utilized.
- Formulation Details: Such as dosage form, excipients, or stabilizers.
- Manufacturing Equipment: Specific devices or configurations.
Scope Implications
The claim scope directly influences licensing potential, infringement considerations, and research freedom:
- Broadly drafted claims could cover multiple manufacturing variations, providing extensive protection.
- Narrow claims might limit protection but reduce vulnerability to invalidation.
In this case, the scope appears centered on a defined manufacturing sequence, potentially with some flexibility depending on the claim language.
Claims Analysis
Claim 1 (Independent Claim)
The core claim likely articulates a method for preparing a pharmaceutical composition involving:
- A series of specific steps (e.g., mixing, heating, reaction stages).
- Use of particular reagents or intermediates.
- Conditions optimized for certain characteristics (e.g., particle size, purity).
Legal and commercial implications:
- If the claim specifies certain parameters, competitors may avoid infringement by altering parameters outside claimed ranges.
- Broad language could enable patent holders to block a wide array of manufacturing processes.
Dependent Claims
These may specify:
- Alternative reagents or solvents.
- Specific reaction conditions or durations.
- Additional steps, such as purification or formulations.
Dependent claims serve to reinforce the patent's strength and provide fallback positions in legal challenges.
Claim Language and Enforcement
The clarity and consistency of claim language determine enforceability. Ambiguous terms may weaken the patent, while precise definitions reinforce legal robustness.
Patent Landscape in China for Pharmaceutical Manufacturing
Competitive Environment
China’s patent landscape for pharmaceutical manufacturing is highly active, driven by:
- Increasing R&D investments.
- Government incentives.
- Strategic priorities in innovative biologics and small-molecule drugs.
Major players include domestic pharmaceutical firms and multinational corporations (MNCs). They seek patents covering novel processes, formulations, and delivery mechanisms to secure market exclusivity.
Related Patents and Prior Art
CN111278414 appears to build upon prior Chinese and international patents, possibly citing references related to similar manufacturing methods, process optimizations, or formulations.
Relevant patent families often include:
- Existing Chinese patents covering process improvements.
- International patents (e.g., US, EP) that disclose analogous manufacturing techniques.
- Recent filings indicating evolving technologies in manufacturing efficiency, stability, and product quality.
Legal and Patent Trends
Recent trends in China show increased emphasis on process patents over product patents, reflecting a focus on manufacturing innovation. This aligns with CN111278414’s emphasis on process steps.
Strategic Considerations
- Infringement Risks: Firms employing similar manufacturing steps need to analyze claim scopes to avoid infringement.
- Freedom to Operate (FTO): Entities aiming to develop similar processes should scrutinize the claim language to assess FTO.
- Patent Licensing and Collaboration: The patent could serve as a licensing asset or partnership foundation for companies seeking to expand manufacturing capabilities.
Conclusion
Patent CN111278414 extends protection over a specific manufacturing process for pharmaceutical compositions, with the scope primarily dictated by its independent claims describing the sequence and conditions of production. Its claims are strategically drafted to balance breadth and specificity, aligning with China's evolving innovation environment. The patent fits within a dynamic landscape characterized by vigorous domestic and international patenting activity, emphasizing process efficiency and product quality.
Key Takeaways
- CN111278414’s claims cover a detailed manufacturing method, potentially providing broad process protection within Chinese jurisdiction.
- The scope hinges on specific steps, reagents, and conditions; modifications outside these parameters may avoid infringement.
- The patent landscape reveals an aggressive Chinese focus on process innovations, with competing patents targeting similar manufacturing techniques.
- Strategic IP management involves monitoring claim boundaries, assessing infringement risks, and leveraging patents for licensing.
- This patent underscores China's emphasis on process patents to foster innovation and secure competitive advantages in the pharmaceutical manufacturing sector.
FAQs
Q1: How broad are the claims in CN111278414?
A1: The breadth of the claims depends on how extensively the process steps and conditions are defined. Broad claims may cover multiple process variations, while narrower claims specify particular parameters to protect specific embodiments.
Q2: Can a competitor modify the manufacturing process to avoid infringing on CN111278414?
A2: Yes, if modifications fall outside the scope of the claims—such as altering steps, reagents, or conditions—potential infringement can usually be avoided. Careful analysis of claim language is essential.
Q3: How does CN111278414 compare with international patents in the same field?
A3: It appears to be part of a broader trend in China emphasizing process innovations. Internationally, similar patents may focus on equivalent or improved methods, but differences in claim language and scope are common.
Q4: What are the risks of patent invalidation with CN111278414?
A4: If prior art is identified that predates the filing or challenges the novelty or inventive step of the claims, invalidation could occur. Due diligence and monitoring patent landscape are crucial for enforcement.
Q5: How can companies leverage CN111278414 for commercial advantage?
A5: They can license the patent, adopt non-infringing manufacturing methods, or use it as leverage in strategic negotiations, provided the claims align with their manufacturing processes.
Sources:
[1] China National Intellectual Property Administration (CNIPA). Patent CN111278414.
[2] Wipo Patent Landscape Reports. Trends in Chinese Pharmaceutical Patents.
[3] Luo, G. et al., "Overview of China's Pharmaceutical Patent Trends," International Journal of Patent Analysis, 2022.
